The Neuroendocrine Effects of Pioglitazone in Patients with Cancer and Cachexia
The goal of this clinical trial is evaluate the effect of pioglitazone compared with placebo on skeletal muscle insulin sensitivity in subjects with cancer and cachexia.
Lung Cancer
DRUG: Pioglitazone 45 mg|DRUG: Placebo
Change in skeletal muscle insulin sensitivity, Quantified using hyperinsulinemic-euglycemic clamp, Baseline, Week 12
The goal of this clinical trial is evaluate the effect of pioglitazone compared with placebo on skeletal muscle insulin sensitivity in subjects with cancer and cachexia.